All patients achieved CD19 negativity within two weeks after CD19 CAR-T cell infusion, confirming the therapy’s short-term efficacy in relapsed/refractory t(8;21) AML with aberrant CD19 expression. This evidence concerns the gene CD19 and acute myeloid leukemia.